SHENZHEN, China--(BUSINESS WIRE)--Tongjitang Chinese Medicines Company (“Tongjitang” or “the Company”; NYSE: TCM), a specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine, announced today that it has removed the non-independent directors, Mr. Yongcun Chen, Mr. Xiaochun Wang and Mr. Justin Yan Chen, from the audit committee, compensation committee and corporate governance and nominating committee, respectively, effective March 14, 2008. Each of these committees is now composed solely of the Company’s two independent directors, Dr. Harry K. Genant and Mr. David Ray White.
